首页> 中文期刊> 《药学学报(英文版)》 >Develop a 3D neurological disease model of human cortical glutamatergic neurons using micropillar-based scaffolds

Develop a 3D neurological disease model of human cortical glutamatergic neurons using micropillar-based scaffolds

         

摘要

Establishing an effective three-dimensional (3D) in vitro culture system to better model human neurological diseases is desirable,since the human brain is a 3D structure.Here,we demonstrated the development of a polydimethylsiloxane (PDMS) pillar-based 3D scaffold that mimicked the 3D microenvironment of the brain.We utilized this scaffold for the growth of human cortical glutamatergic neurons that were differentiated from human pluripotent stem cells.In comparison with the 2D culture,we demonstrated that the developed 3D culture promoted the maturation of human cortical glutamatergic neurons by showing significantly more MAP2 and less Ki67 expression.Based on this 3D culture system,we further developed an in vitro disease-like model of traumatic brain injury (TBI),which showed a robust increase of glutamate-release from the neurons,in response to mechanical impacts,recapitulating the critical pathology of TBI.The increased glutamate-release from our 3D culture model was attenuated by the treatment of neural protective drugs,memantine or nimodipine.The established 3D in vitro human neural culture system and TBI-like model may be used to facilitate mechanistic studies and drug screening for neurotrauma or other neurological diseases.

著录项

  • 来源
    《药学学报(英文版)》 |2019年第3期|557-564|共8页
  • 作者单位

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Department of Biological Engineering, Utah State University, Logan, UT 84322, USA;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Institute for Stem Cell and Neural Regeneration, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

    Department of Biological Engineering, Utah State University, Logan, UT 84322, USA;

    Physical Sciences and Engineering Division(PSE), King Abdullah University of Science and Technology, Thuwa123955-6900, Kingdom of Saudi Arabia;

    Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号